Noxopharm Ltd. (AU:NOX)
ASX:NOX
Top Page
Noxopharm Ltd.
(Sydney:NOX)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.06
▼(-36.67% Downside)
Action:ReiteratedDate:02/11/26
The score is primarily held down by weak financial performance (persistent losses, ongoing cash burn, and a 2025 deterioration in balance-sheet strength with higher leverage). Technicals also point to a weak trend with negative/soft momentum, while valuation support is limited because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Focused oncology R&D platform
Noxopharm’s clear, durable strategic focus on oncology therapeutics—small-molecule candidates that augment radiotherapy and immuno-oncology—creates a coherent R&D roadmap and candidacy logic that can attract partnership, trial design efficiency, and long-term niche positioning in cancer adjunct therapies.
Negative Factors
Deteriorated balance sheet and high leverage
Material balance-sheet deterioration and debt roughly 3.6x equity sharply increase financial risk. Elevated leverage reduces flexibility to fund R&D internally, heightens refinancing or covenant risk, and increases the likelihood of dilutive or costly external financing—constraining long-term pipeline development options.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused oncology R&D platform
Noxopharm’s clear, durable strategic focus on oncology therapeutics—small-molecule candidates that augment radiotherapy and immuno-oncology—creates a coherent R&D roadmap and candidacy logic that can attract partnership, trial design efficiency, and long-term niche positioning in cancer adjunct therapies.
Read all positive factors
Noxopharm Ltd. (NOX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$18.13M
Dividend YieldN/A
Average Volume (3M)123.50K
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue GrowthN/A
EPS Growth-36.89%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding307,237,950
10 Day Avg. Volume89,571
30 Day Avg. Volume123,503
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)22.89
Price to Sales (P/S)5.60
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Noxopharm Ltd. Business Overview & Revenue Model
Company Description
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherap...
How the Company Makes Money
null...
Noxopharm Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.82M | 2.40M | 6.01M | 5.43M | 5.61M |
| Gross Profit | -1.45M | -534.81K | 5.86M | 5.17M | 5.35M |
| EBITDA | -5.38M | -5.95M | -20.85M | -23.70M | -5.85M |
| Net Income | -4.88M | -3.58M | -15.06M | -18.67M | -9.35M |
Balance Sheet | |||||
| Total Assets | 4.58M | 6.78M | 10.13M | 26.59M | 47.85M |
| Cash, Cash Equivalents and Short-Term Investments | 1.55M | 2.32M | 3.01M | 14.01M | 26.80M |
| Total Debt | 2.48M | 0.00 | 0.00 | 160.62K | 349.31K |
| Total Liabilities | 3.89M | 1.29M | 1.06M | 2.48M | 7.08M |
| Stockholders Equity | 689.96K | 5.50M | 9.07M | 24.12M | 40.78M |
Cash Flow | |||||
| Free Cash Flow | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Operating Cash Flow | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Investing Cash Flow | 2.48M | 0.00 | 123.51K | 0.00 | 225.23K |
| Financing Cash Flow | 2.60M | 0.00 | -178.09K | 975.73K | 28.32M |
Noxopharm Ltd. Technical Analysis
Negative
0.09
Price Trends
0.07
Negative
0.08
Negative
0.08
Negative
Market Momentum
>-0.01
Negative
40.99
Neutral
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NOX, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and above the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.99 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NOX.
Noxopharm Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$41.40M | -25.86 | 10.35% | 2.81% | 0.65% | -9.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$8.84M | -0.15 | 2844.96% | ― | ― | 46.28% | |
43 Neutral | AU$18.13M | -3.69 | 2509.60% | ― | ― | -36.89% | |
42 Neutral | AU$55.73M | -5.28 | -62.49% | ― | ― | 10.78% | |
42 Neutral | AU$84.50M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
41 Neutral | AU$137.36M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:NOX
Noxopharm Ltd.
0.06
-0.02
-27.16%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
12.77%
AU:CHM
Chimeric Therapeutics Ltd.
―
―
―
AU:EZZ
EZZ Life Science Holdings Ltd.
0.88
-0.64
-41.99%
AU:RCE
Recce Pharmaceuticals Ltd.
0.48
0.12
33.43%
AU:ALA
Arovella Therapeutics Limited
0.07
>-0.01
-12.50%
Noxopharm Ltd. Corporate Events
Noxopharm Half-Year Loss Widens as Net Tangible Assets Turn Negative
Feb 27, 2026
Noxopharm Limited reported a sharp widening of its half-year loss to $1.84 million for the period ended 31 December 2025, a 49% increase from the prior corresponding period’s $1.24 million loss. The company’s net tangible assets per sh...
Noxopharm Issues 15 Million New Shares Under Financing Facility
Feb 27, 2026
Noxopharm Limited has issued 15 million fully paid ordinary shares at an issue price of zero dollars per share under a financing facility announced on 27 February 2026, expanding its capital base without providing a disclosure document to investor...
Noxopharm Issues 15 Million New Shares Under Financing Facility
Feb 27, 2026
Noxopharm Ltd has applied for quotation on the ASX of 15 million new ordinary fully paid shares issued on 27 February 2026. The shares were created in connection with a new financing facility, with the share issue and execution of the related faci...
Noxopharm Secures $2.8m R&D Rebate to Advance Sofra Clinical Programs
Feb 27, 2026
Noxopharm has received a $2.8 million rebate under the Australian Government’s RD Tax Incentive scheme for FY2025, bolstering its cash reserves as it advances its Sofra technology platform and HERACLES clinical program. The funding supports ...
Noxopharm Secures Flexible $5m At-the-Market Equity Facility with Acuity Capital
Feb 27, 2026
Noxopharm Limited has entered into an At-the-Market Subscription Agreement with Acuity Capital, securing access to up to $5 million in standby equity capital over a five-year period to July 2031. The facility gives the company full discretion over...
Noxopharm’s Sofra Platform Science Published in Top Immunology Journal
Feb 10, 2026
Noxopharm has announced that the breakthrough science underpinning its Sofra platform has been published in Nature Immunology, a leading peer-reviewed journal in the field. The paper, led by Professor Michael Gantier of the Hudson Institute with c...
Noxopharm Clears Key Safety Milestone as HERACLES Trial Concludes and Sofra Platform Gains Global Traction
Jan 30, 2026
Noxopharm reported a strong December quarter, highlighted by the successful completion of dosing in all cohorts of its milestone HERACLES clinical trial evaluating SOF-SKN™, which delivered highly positive safety and tolerability results and...
Noxopharm Clears Safety Milestone as HERACLES Trial for SOF-SKN Concludes
Jan 20, 2026
Noxopharm has successfully completed the clinical component of its HERACLES trial, reporting that the second and final multiple-dose cohort of its topical drug candidate SOF-SKN was safe and well tolerated across all dosing groups. The positive sa...
Noxopharm Rolls Over $2.6m in Convertible Notes, Flagging Potential Share Dilution
Jan 1, 2026
Noxopharm has issued 2.6 million new convertible notes with a face value of $1 each and 520,000 unlisted options to sophisticated and professional investors, rolling over an equivalent value of maturing notes first issued in January 2025. The note...
Noxopharm Issues New Unquoted Options and Convertible Notes
Jan 1, 2026
Noxopharm Limited has notified the market of the issue of 520,000 unquoted options, exercisable at A$0.1488 and expiring on 10 September 2027, along with 2.6 million unquoted convertible notes, both dated 2 January 2026. The new options and conver...
Noxopharm Redeems 2.6 Million Convertible Notes, Trimming Convertible Debt
Jan 1, 2026
Noxopharm Limited has notified the market that 2.6 million NOXAH convertible notes have ceased following repayment or redemption without conversion, effective 2 January 2026. The cessation of these convertible debt securities indicates a reduction...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.